Drug Trial Radar · NCT07362017
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Feb 17, 2026
Primary completion
Aug 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
Conditions
- Moderate-to-severe Chronic Plaque Psoriasis
Interventions
PonesimodDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of ponesimod as measured by reporting of adverse events (AEs)Time frame: Through study completion, approximately 1 year
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Vanda Investigational Site
Glendale, Arizona · Recruiting
Vanda Investigational Site
Fremont, California · Recruiting
Vanda Investigational Site
Miami, Florida · Recruiting
Vanda Investigational Site
Indianapolis, Indiana · Recruiting
Vanda Investigational Site
Portsmouth, New Hampshire · Recruiting
Vanda Investigational Site
Rochester, New York · Recruiting
Vanda Investigational Site
Wilmington, North Carolina · Recruiting
Vanda Investigational Site
San Antonio, Texas · Recruiting
Vanda Investigational Site
Webster, Texas · Recruiting
Vanda Investigational Site
Spokane, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.